HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Yanji Pharmaceutical and Health Cluster

Active ingredients, excipients and sterile packaging enter formulation, filling and sterilization; therapy elements and medical polymers are assembled and electrically checked, while cell samples are received, prepared and cryogenically stored. The resulting injectable and oral medicines, home-therapy equipment, storage certificates, prepared samples and quality reports serve healthcare providers, pharmaceutical distributors, home-health channels, research partners and authorized sample clients.

Formation and regional foundations

Yanji Pharmaceutical and Health Cluster appears in authority list dated 2026, and each named entity uses its corresponding public record.

The authority list uses the name Yanji Pharmaceutical and Health Cluster. A working review can begin with active ingredients and formulation and filling.

Core geography: Pharmaceutical-manufacturing and medical-device area of Yanji High-Tech Industrial Development Zone

Yanji Pharmaceutical and Health Cluster operating-chain map

Six supply-and-demand connections in Yanji Pharmaceutical and Health Cluster

The map for Yanji Pharmaceutical and Health Cluster lists inputs, operations, a named entity, outputs, demand and delivery conditions in sequence.

  • active ingredients — Input review for Yanji Pharmaceutical and Health Cluster centres on active ingredients and checks material identity, compliance documents, lot and storage or transport conditions before work begins.
  • formulation and filling — Operations for Yanji Pharmaceutical and Health Cluster follow formulation and filling and record controlled steps, validation status, environmental conditions and deviation handling at each handoff.
  • injectable and oral medicines — Output scope for Yanji Pharmaceutical and Health Cluster covers injectable and oral medicines, with intended scope, test results, release documents and storage or transport requirements defined separately.
  • healthcare providers — Demand for Yanji Pharmaceutical and Health Cluster comes from healthcare providers, with specifications and delivery terms checked against research, production, clinical or regulatory use conditions.
  • injectable medicines acceptance criteria — Acceptance for Yanji Pharmaceutical and Health Cluster follows injectable medicines acceptance criteria, with measurement and retest results linked to a controlled lot or validated revision.
  • injectable medicines delivery arrangements — Delivery for Yanji Pharmaceutical and Health Cluster follows injectable medicines delivery arrangements and checks release status, temperature control, protection, handover and traceability files.

01 · Yanji Pharmaceutical and Health Cluster: Inputs and inbound terms

This chapter reviews input mix and inbound conditions for Yanji Pharmaceutical and Health Cluster.

Input mix: active ingredients, pharmaceutical excipients, sterile packaging, heating and therapy elements, medical polymers, cell samples and cryopreservation consumables.

For the path from active ingredients through formulation and filling to injectable and oral medicines, first check material identity, compliance documents, lot and storage or transport conditions, retain practical samples and verify sites, equipment or services through records and field conditions.

In Jilin, physical inputs such as active ingredients carry a lot trail through packaging, transport and traceability records, while sites, equipment or services retain their own reference numbers.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, material identity, compliance documents, lot and storage or transport conditions should be explicit.

02 · Yanji Pharmaceutical and Health Cluster: Operations and handoffs

This chapter reviews production stages and engineering interfaces for Yanji Pharmaceutical and Health Cluster.

Operating sequence: formulation and filling, sterilization, device assembly and electrical checks, sample intake, cell preparation, cryogenic storage and quality review.

After a change to formulation and filling, reassess injectable medicines acceptance criteria and update records for controlled steps, validation status, environmental conditions and deviation handling.

Before formulation and filling in Jilin moves to injectable and oral medicines, use a limited trial, test harvest or stage result to confirm the output boundary.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, equipment, software versions and accountable owners should be explicit.

03 · Yanji Pharmaceutical and Health Cluster: Outputs and acceptance

This chapter reviews output forms and acceptance measures for Yanji Pharmaceutical and Health Cluster.

Output range: injectable and oral medicines, home physiotherapy equipment, cell-storage certificates, prepared samples and quality reports.

Acceptance of injectable and oral medicines from formulation and filling in Jilin should specify reproducible samples, methods, environments and decision rules.

Review of injectable and oral medicines separately covers registration or filing boundaries, specifications, lot records, storage and transport conditions, and user support.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, specifications, test environments and delivery documents should be explicit.

04 · Yanji Pharmaceutical and Health Cluster: Demand and purchasing

This chapter reviews demand side and purchasing routes for Yanji Pharmaceutical and Health Cluster.

Demand side: healthcare providers, pharmaceutical distributors, home-health channels, research partners and authorized sample clients.

In Jilin, demand from healthcare providers can be separated by research, production, clinical or regulatory use conditions, then matched to the conditions for injectable and oral medicines.

An inquiry from healthcare providers for injectable and oral medicines should state acceptance and delivery terms as well as volume and price.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, use case, volume range and acceptance owner should be explicit.

05 · Yanji Pharmaceutical and Health Cluster: Named entities

The three named entities for Yanji Pharmaceutical and Health Cluster each link to their own public material.

Jilin Aodong Pharmaceutical Group Yanji Co., Ltd: Holds approvals for multiple medicines and handles formulation production, quality release and market supply, including injectables.

Yanbian Kexi'an Medical Devices Co., Ltd: Manufactures home physiotherapy devices at its inspected site under a documented production and quality system.

Carson (Jilin) Cell Resource Bank Management Co., Ltd: Develops cell-storage and preparation facilities in the high-tech zone for sample intake, controlled preservation and downstream translation.

  • The three named entities for Yanji Pharmaceutical and Health Cluster use only relationships directly stated in their own material.

06 · Yanji Pharmaceutical and Health Cluster: Quality and records

This chapter reviews quality review and technical files for Yanji Pharmaceutical and Health Cluster.

When buying medicine formulations, physiotherapy devices and cell-storage and preparation services, review medicine-approval scope, sterility assurance, assay and impurities, device electrical safety, sample identity, storage temperature and custody records.

When operating conditions for formulation and filling in Jilin change, reassess injectable medicines acceptance criteria and update controlled steps, validation status, environmental conditions and deviation handling.

After release of injectable and oral medicines from formulation and filling in Jilin, set retesting, exception isolation and correction deadlines so responsibility remains traceable to a controlled lot or validated revision.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, samples, test conditions and decision rules should be explicit.

07 · Yanji Pharmaceutical and Health Cluster: Delivery and site handover

This chapter reviews transport, delivery and site handover for Yanji Pharmaceutical and Health Cluster.

Medicines ship sealed within labelled temperature ranges, devices use shock-resistant packs, and cell samples travel in validated low-temperature vessels with continuous temperature records.

When delivery of injectable and oral medicines from formulation and filling in Jilin spans several traceable units or service stages, every deliverable should link back to its record.

Delivery of injectable and oral medicines to healthcare providers keeps packaging integrity, lot labels, storage temperature, transit time and arrival checks linked.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, packaging, temperature, humidity, shock protection and arrival checks should be explicit.

08 · Yanji Pharmaceutical and Health Cluster: Engagement and due diligence

This chapter reviews engagement sequence and due-diligence list for Yanji Pharmaceutical and Health Cluster.

Before signing, also confirm medicine and device registrations, production-site status, lot testing, sample consent, permitted cell uses, data-access controls and incident-handling responsibilities.

When checking entities including Jilin Aodong Pharmaceutical Group Yanji Co., Ltd, cluster designation does not prove performance; before quoting injectable and oral medicines, assign responsibility for injectable medicines acceptance criteria and injectable medicines delivery arrangements.

In Pharmaceutical-manufacturing and medical-device area of Yanji High-Tech Industrial Development Zone, an engagement for injectable and oral medicines from formulation and filling can begin with a small lot, pilot or stage deliverable before capacity, lead time and longer arrangements are set.

  • Before Yanji Pharmaceutical and Health Cluster moves into execution, separate conclusions on regional designation and company capability should be explicit.

Sources and reading notes

Yanji Pharmaceutical and Health Cluster follows the name used in the authority list, records the three companies only by complete legal name and directly stated relationship, and leaves capacity, pricing and engagement terms for separate checks.

  • Yanji Pharmaceutical and Health Cluster is the cluster name used in the 2026 authority list.
  • The corresponding public record states this relationship for Jilin Aodong Pharmaceutical Group Yanji Co., Ltd: Yanji | Holds approvals for multiple medicines and handles formulation production, quality release and market supply, including injectables.
  • The corresponding public record states this relationship for Yanbian Kexi'an Medical Devices Co., Ltd: Yanji | Manufactures home physiotherapy devices at its inspected site under a documented production and quality system.
  • The corresponding public record states this relationship for Carson (Jilin) Cell Resource Bank Management Co., Ltd: Yanji | Develops cell-storage and preparation facilities in the high-tech zone for sample intake, controlled preservation and downstream translation.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.